| University of Alabama | $139,000 for the study of targeting ncRNA as a curative therapy for metastatic breast cancer |
| Baylor College of Medicine | $81,000 for the study of RAF inhibition as a novel mechanism for treating neuroblastoma |
| Boston University | $167,000 for the study of a single cell RNA-sequence analysis of tumor-immune microenvironment in state I non-small cell lung cancer patients |
| Central Michigan University | $171,000 for the study of UNK expression and timing of breast cancer recurrence |
| Duke University | $175,000 for immune surveillance in obesity-associated cancer |
| Idaho State University | $98,000 for targeting sphingolipid metabolism in synovial sarcoma |
| Mayo Clinic | $159,000 for the study of the guanylyl cyclase A receptor activator ZD100 – a novel therapeutic agent in multiple myeloma therapy for breast cancer |
| Northwestern University | $152,000 for novel targeted combination therapies based on PIM kinase inhibition |
| Virginia Commonwealth University | $187,000 for targeting miR-204-5p suppresses the tumorigenesis and metastasis of head and neck cancer |